摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2S,4S)-4-azido-2-isopropyl-4-[(2S,4S)-4-isopropyl-5-oxotetrahydrofuran-2-yl]butanal | 173154-02-4

中文名称
——
中文别名
——
英文名称
(2S,4S)-4-azido-2-isopropyl-4-[(2S,4S)-4-isopropyl-5-oxotetrahydrofuran-2-yl]butanal
英文别名
(S)-2-[(S)-2-azido-2-((2S,4S)-4-isopropyl-5-oxo-tetrahydro-furan-2-yl)-ethyl]-3-methyl-butyraldehyde;3(S)-isopropyl-5(S)-[1(S)-azido-3(S)-isopropyl-4-oxo-butyl]-tetrahydrofuran-2-one;2-[2-azido-2-(4-isopropyl-5-oxotetrahydrofuran-2-yl)ethyl]-3-methylbutyraldehyde;3(S)-isopropyl-5(S)-[1(S)-azido-3(S)-isopropyl-4-oxobutyl]-tetrahydrofuran-2-one;2-[2-azido-2(4-isopropyl-5-oxotetrahydrofuran-2-yl)ethyl]-3-methylbutyraldehyde;(2S,4S)-4-azido-4-[(2S,4S)-5-oxo-4-propan-2-yloxolan-2-yl]-2-propan-2-ylbutanal
(2S,4S)-4-azido-2-isopropyl-4-[(2S,4S)-4-isopropyl-5-oxotetrahydrofuran-2-yl]butanal化学式
CAS
173154-02-4
化学式
C14H23N3O3
mdl
——
分子量
281.355
InChiKey
YIAQHWCGFUMFNU-VOAKCMCISA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    20
  • 可旋转键数:
    7
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.86
  • 拓扑面积:
    57.7
  • 氢给体数:
    0
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amides
    申请人:Ciba-Geigy Corporation
    公开号:US05559111A1
    公开(公告)日:1996-09-24
    .delta.-Amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amides of formula I ##STR1## and the salts thereof, have renin-inhibiting properties and can be used as antihypertensive medicinal active ingredients.
    公式I的.delta.-氨基-.gamma.-羟基-.ω-芳基-烷基酸酰胺及其盐具有抑制肾素的性质,可用作降压药物活性成分。
  • [EN] METHODS OF TREATING ALZHEIMER'S DISEASE USING ARYL ALKANOIC ACID AMIDES<br/>[FR] METHODES DE TRAITEMENT DE LA MALADIE D'ALZHEIMER PAR DES AMIDES D'ACIDE ARYL ALCANOIQUE
    申请人:ELAN PHARM INC
    公开号:WO2003103653A1
    公开(公告)日:2003-12-18
    Disclosed are methods for treating Alzheimer’s disease, and other diseases, and/or inhibiting beta-secretase enzyme, and/or inhibiting deposition of A beta peptide in a mammal, by use of compounds of formula 1 (1) wherein the variables R1-R8 and X are defined herein.
    揭示了一种治疗阿尔茨海默病和其他疾病,和/或抑制β-分泌酶,和/或通过使用式1(1)中定义的化合物在哺乳动物体内抑制Aβ肽的沉积的方法。其中变量R1-R8和X在此处定义。
  • Organic Compounds
    申请人:Maibaum Juergen Klaus
    公开号:US20090076062A1
    公开(公告)日:2009-03-19
    Disclosed are δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amide compounds of formula (I) and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and methods of administering them for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.
    揭示了具有抑制肾素作用的δ-氨基-γ-羟基-ω-芳基-烷酸酰胺化合物的化学式(I)及其盐。还揭示了包括这些化合物的药物组合物以及用于治疗高血压、动脉粥样硬化、不稳定性冠状动脉综合征、充血性心力衰竭、心肌肥大、心脏纤维化、心肌梗死后心肌病、不稳定性冠状动脉综合征、舒张功能障碍、慢性肾病、肝纤维化、糖尿病并发症(如肾病、血管病和神经病变)、冠状血管疾病、血管成形术后再狭窄、眼内压升高、青光眼、异常血管生长、高醛固酮症、认知障碍、阿尔茨海默病、痴呆症、焦虑状态和认知障碍的治疗方法。
  • METHOD FOR PREPARING ALISKIREN AND ITS INTERMEDIATES THEREOF
    申请人:Tu Yongjun
    公开号:US20130225841A1
    公开(公告)日:2013-08-29
    A method for preparing Aliskiren and intermediate thereof, which comprises the following steps: reacting 4-bromo-1-methoxy-2-(3-methoxypropoxy)benzene with magnesium isopropyl chloride and n-BuLi to obtain the compound of formula XXII; reacting the product of methylsulfonylation of the compound of formula XIX with anhydrous LiBr to obtain the compound of formula XXI; obtaining the intermediate of Aliskiren shown as formula XV by reacting the compound of formula XXII with the compound of formula XXI in an ether as the solvent and in the presence of a catalyst containing iron; then reacting the compound of formula XV with the compound of formula VII to obtain the compound of formula XXIII, following removing R 1 from the amino group and obtaining Aliskiren shown as formula I.
    一种制备阿利司琼及其中间体的方法,包括以下步骤:将4-溴-1-甲氧基-2-(3-甲氧基丙氧基)苯基与异丙基氯化镁和n-BuLi反应,得到化合物XXII的步骤;将化合物XIX的甲磺酰化产物与无水溴化锂反应,得到化合物XXI的步骤;通过在醚溶剂中,在含有铁催化剂的情况下,将化合物XXII与化合物XXI反应,得到阿利司琼的中间体,其化学式如XV所示;然后将化合物XV与化合物VII反应,得到化合物XXIII,随后去除氨基上的R1,得到化学式为I的阿利司琼。
  • Electronic and steric effects on the intramolecular Schmidt reaction of alkyl azides with secondary benzyl alcohols
    作者:Xiaowei Sun、Chengzhe Gao、Fan Zhang、Zhuang Song、Lingyi Kong、Xiaoan Wen、Hongbin Sun
    DOI:10.1016/j.tet.2013.11.098
    日期:2014.1
    The intramolecular Schmidt reaction of simple azido secondary benzyl alcohols has been realized for the first time. Investigation of the electronic and steric effects of the substrates on the product outcome was conducted. Unique intramolecular Schmidt rearrangements were observed with the formation of a cinnamaldehyde derivative and aryl aldehydes, respectively. Using this protocol, an efficient synthesis
    简单的叠氮基仲苄醇的分子内Schmidt反应已首次实现。研究了底物对产品结果的电子和空间效应。观察到独特的分子内施密特重排,分别形成肉桂醛衍生物和芳基醛。使用该协议,实现了二氢苯并三嗪衍生物的有效合成。此外,还获得了一种用于2-芳基-1-吡咯啉的实用方法。
查看更多